Effects Of E-Adrenoceptor Antagonists On Exercise

Question:

Discuss the Effects of E.Adrenoceptor Antagonists On Exercise Induced Cardiovascular Disorders

Answer:

Introduction

Don't use plagiarized sources. Get Your Custom Essay on
Effects Of E-Adrenoceptor Antagonists On Exercise
Just from $8/Page
Order Essay

Beta-blockers, drugs that block the binding norepinephrine/epinephrine receptors, bind beta -adrenoceptors.

They cause inhibition of the effects that act on the receptors.

Beta blockers can be considered sympatholytic drugs.

Beta blockers can bind to beta receptors, which partially activates them. However, norepinephrine cannot be bound to these receptors.

These partial agonists create a background for sympathetic activity, while also preventing normal and enhanced sympathetic activities.

While beta blockers may have some intrinsic sympathomimetic activity, others can produce stabilizing activities. These activites are similar to the membrane stabilization activity of sodium channels blockers.

Beta blockers attach to beta receptors located in the heart area surrounding nodal tissue. They conduct the system and allow for contraction of myocytes.

The beat is thought to contain both b1 (or b2) adrenoceptors.

It acts by binding to norepinephrine and releases it to sympathetic nerves within the adrenergic zone.

In this instance, beta blockers provide binding protection for normal ligands b–adrenoceptors by competing with the binding sites.

Gs protein, which is able to activate adenyl cyclase forming camp in the ATP, is coupled with beta adrenoceptors. This activation increases Camp and activates dependent protein kinase.

These beta-blockers can reduce the sympathetic influence that stimulates the heart’s rate, contractility, electrical conduction, relaxation, and heart rate.

This can result in a decrease in heart rate and contractility, velocity conection, relaxation, and contractility.

These drugs can be used to lower sympathetic activity.

Beta blockers can have a limited effect on vascular health. This is due to the fact that the basal blood tone modulator functions in a very small way through the b2 receptors.

A lower degree of vasoconstriction within the vascular beds is associated with blockage of b2adrenoceptors.

Studies have shown that the intensity of vascular activation is linked to b1 adrenoceptor receptors. It stimulates in response both to constriction and relaxation.

[v] Endothelial tissues are not created through the mediation of the b1 adrenoceptors. Instead, they play an important role in influcning blood vessels activity. Furthermore, the role played in the prevention and treatment of cardiovascular disease is key. It is therefore necessary to evaluate the different morphologies of cardiac function when determining the effects of the b1 adrenoceptors.

By lowering blood pressure, beta-adrenoceptor receptor antagonists are useful in cardiovascular management.

Atenol and other compounds selectively target Beta 1-adrenoceptor that possess intrinsic sympathomimetic ability.

Pindol however, which has sympathomimetic activity and does not have a selective beta-adrenoceptor ability, is non-selective.

This study evaluates the effectiveness of Pindol in exercise and rest. It also examines the therapeutic and medical effects of both drugs.

The placebo control is used as a control in the double blind study.

This study examines the effects of Pendolol and Atenolol (orally administered b adrenoceptors antagonists) on blood pressure effects, heart beat, and lung function during rest and exercise.

Methods and Materials

The University of New South Wales health science department received the study experiment for ethical approval.

The double blind design of this experiment was used. Subjects were blinded, and they used placebo and control.

Students aged 18 to 65 years were the subjects.

Perceived Exertion Scale, heart monitor having strap and polar, pulse monitor with watch, strap, and polar, bloodpressure monitor, peak flowmeter, and a timer were all needed for this study.

The experimental phase consisted of two stages: pre drug and after drug.

Pre drug phase: Start the timer at 0 minute, adjust the time to the resistance level, and then hold the KP level at 50% for 2 minutes.

The last 10 seconds are used to record the heart rate (EHR), as well as exertion level.

Recoding the resting heart beat (RHR) takes place at 15 minutes. At 30 minutes, RHR, oxygen, blood pressure and lung function are taken.

Next, do a bike workout while your KP levels remain at 2.

After the drug has been consumed, measurements are taken at 15 minutes. These measures record the RHR and oxygen saturation levels, blood pressure, and lung function tests for the participant. The assessments are again done at 45, 45, 75, and 90 minute intervals post-drug ingestion.

After 90 minutes, start the bike at KP levels for two minutes. Then take the assessments of HER and oxygen saturation.

Results

Pre-drug treatment results

Rate of resting heart rate

mmHg

PEFR

EHR

Fatigue

Rest

Average

Table 1 illustrates the pre-drug evaluation of the different assessment indicators.

Keys: ROS(rate of oxygen saturation), PEFR(Peak expiratory speed rate), EOS (exercise oxygen saturation) and HER– (heart rate).

Results from Post-Drug Treatment

SBP/DBP, mmHg

Vitamin B6

Atenolol

Average

Table 2: Blood pressure assessment

RHR beats/min

Vit B6

Atenolol

Average

Table 2 – Resting heart rate

Vit B6

Atenolol

Average

Table 3: The peak expiratory rate

Vit B6

Atenolol

Average

Table 4: Oxygen saturation rate

Resting Heart Rate

Time

Rate of resting heart rate

Vit B6

Atenolol

Average

Table 5: Resting heart rate

Vitamin B6

Atenolol

Average

Table 6 shows the levels of exercise saturation

Assessments: Exercise Fatigue Levels

Fatigue

Vitamin B6

Atenolol

Average

Table 7: Exercise fatigue levels

Discussion

Results show elevated blood pressure due to treatment intake.

Pre-drug assessments showed an average blood pressure of 117/75. On drug administration, blood pressure dropped significantly to 109/68 when Atenol was administered and Pendalol (at 103/66 beta blocks) was administered.

Low blood pressure is defined as 90/60 or below. A blood pressure of 90/60 to 120/80 indicates ideal blood pressure. A blood pressure of 140/90 or higher signifies high blood pressure.

Atenolol’s peak expiratory flow rate was 451L/min and Pednalol’s 438 L/min.

These results were similar at the pre-drug phase, where an average of 44L/min was recorded. This signifies a greater effect of beta blockers upon lung functionality.

Pre drug treatment had an average heart beat rate of 215 beats/min, 127 beats/min (for the placebo), 110 beats for Atenolol and 99 beats/minute (for pendadol).

Beta blockers had a higher effect on drug administration, as they decreased the heart beats of sample participants.

In hypertension management, B-Blockers are the most commonly used drugs to lower blood pressure.

These results have shown that b-Blockers can lower blood pressure.

Both systolic as well as diastolic blood pressures are lower, which is indicative of a change effect.

Its pharmacological effects are due to its intrinsic sympathomimetic activities. These properties block the production of nitrix dioxide and have hydrophilic, lipophilic and blood-saving properties.

The combination of activity levels and cardio respiratory effects improves health outcomes.

Peak expiratory rate refers to the speed at which the airway is forced to exhale.

This is a measure of airway flow. It relies on voluntary effort and muscular abilities.

Expiratory maneuver is what determines maximum airflow.

Average peak expiratory rates for medication were 97.6% with Atenol drug; 97% with pendadol drugs and 97.4% with Vitamin B 6.

The average peak expiratory rates are 97% and 97% respectively, with no significant differences to those of pre-drug administration.

Atenolol’s and Pendadol’s average resting heart rates are 110 betas/min and 97beats/min respectively, compared to the placebo which is 127 beats/min.

The heart beat rate of pre-drug assessment was 215 beats/min. This indicates that there are lower levels of heart beat rates.

Atenolol drug pendalol has an oxygen saturation rate of 97%. This is compared with the placebo level at 97.5%.

Pre drug assessment showed that 97% was the average, with no difference.

The average fatigue level during exercise was 12.3 on Atenolol drug while it was 11.5 on Pendalol. That is compared to 10.7 on placebo.

Pre-drug evaluations showed no significant difference in fatigue levels, with an average of 11.2 levels.

Comparisons of the effect of different intrinsic bblockers on cardiovascular patients have shown that they all have similar effects on their cardiovascular activity.

The heart beat rate was significantly reduced when it is combined with exercise therapy.

In testing the effects of treatment for cardiovascular patients, exercise has predominantly been used.

This experiment highlights the significant impact of eadrenoceptor inhibitors on exercise-induced cardiovascular change.

Beta adrenoceptor can have important effects on cardiovascular health. This includes lowering blood pressure and reducing heart beat.

The binding of beta-blockers to the receptors of norepinephrine/epinephrine does not change with physical activity.

Refer to

Rabbit as a model for studying cardiac b3-adrenoceptors.

The future of contractility: New insights into the mechanism of action of carvedilol for chronic heart failure patients – a matter of time.

Journal of cardiac disease, 18(3), 193-193.

Neuroendocrine response of patients with untreated severe and persistent congestive heart disease and chronic constrictive pericarditis to standing and light exercise.

Meta-analysis of randomised controlled trials showing the effects of beta-blockers in endothelial function

Cardiology journal, 22(6). 708-716.

Randomized, Double-Blind Comparison of Acute Blockade With 50mg Metoprolol Tartrate in Normal Subjects vs 25m Carvedilol

Congestive Heart Failure (12(5), 254-257

Cardio?Selective Beta Blocker: Pharmacological Evidence, Their Influence and Exercise Capacity.

Cardiovascular therapeutics, 31(2). 76-83.

Comparison of long-term effects between nebivolol (and carvedilol) in patients with hypertensive cardiac failure.

Journal of cardiac failure 17(9), 703-709.

Potential Use of Adrenoceptor Antagonists b3 in Heart Failure Therapy

Cardiovascular Therapeutics 20(1), 19–26.

Studies and meta-analyses on b-Blockers and hypertension over the years.

Canadian Journal of Cardiology, 30, 5, S16-S2

Postgraduate medical journals, 91(1081): 627-633.